C-reactive protein and rapidly progressive coronary artery disease is there any relation?
| Autor: | Michael N. Zairis, Constantine N. Fakiolas, Evangelos G. Pissimissis, Stavros J. Manousakis, Evangelos Tsanis, Stefanos G. Foussas, Alexander Stefanidis, Denis Vitalis, Seraphim M. Hadjigeorgiou, Christopher D. Olympios |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Clinical Investigations Coronary Disease Coronary Angiography Risk Assessment Coronary artery disease Lesion Risk Factors Internal medicine Blood plasma medicine Humans Angioplasty Balloon Coronary Coronary atherosclerosis Aged biology business.industry C-reactive protein Percutaneous coronary intervention General Medicine Odds ratio Middle Aged medicine.disease Surgery Stenosis C-Reactive Protein Multivariate Analysis Disease Progression Cardiology biology.protein Female medicine.symptom Cardiology and Cardiovascular Medicine business |
| Zdroj: | Clinical Cardiology. 26:85-90 |
| ISSN: | 1932-8737 0160-9289 |
| DOI: | 10.1002/clc.4960260208 |
| Popis: | Background: High plasma C‐reactive protein (CRP) levels have been associated with an unfavorable outcome in patients with coronary artery disease (CAD), and a direct participation of CRP in the atherosclerotic process has been postulated. Hypothesis: The aim of this study was to evaluate the possible relationship of high plasma CRP levels with the rapid progression of coronary atherosclerosis (RPCAD). Methods: In all, 194 patients who were readmitted and underwent repeat coronary angiography because of recurrence of symptoms following successful percutaneous coronary intervention were studied. Median angiographic follow‐up time was 6 months. Rapid progression CAD was defined as the presence of a new lesion, > 25% in luminal diameter stenosis, in a previously nondiseased vessel, or deterioration of a known, nontreated lesion by at least 25%. Results: By multivariate analysis, patients with high plasma CRP levels upon first admission were at higher risk of RPCAD. In particular, odds ration (OR) = 1.8; 95% confidence interval (CI) = 1.3‐3.6; p value = 0.02 in patients with CRP = 0.5‐2 mg/dl versus patients with CRP < 0.5 mg/dl, and OR = 7.1; 95% CI = 3.8‐9.5; p value < 0.001 in patients with CRP > 2 mg/dl versus patients with CRP < 0.5 mg/dl. Conclusion: Increased plasma CRP levels could possibly identify patients at high risk for the development of RPCAD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|